AGA临床实践更新:成人艰难梭菌感染管理专家综述
该专家综述由AGA临床实践更新委员会委托,基于专家意见和文献回顾制定,未进行系统评价,故建议无正式证据质量或强度评级。内容涵盖艰难梭菌感染的预防(屏障防护、杀孢子消毒、手卫生)、诊断(临床诊断结合多步检测,不一致但高临床怀疑者应治疗)、分型(白细胞>15,000 cells/uL和/或肌酐>1.5倍基线为重度,休克、肠梗阻或巨结肠为暴发型)、治疗(非达霉素200 mg每日两次口服10天为首选,万古霉素125 mg每日四次口服10天也可接受,甲硝唑仅用于暴发型)、复发管理及粪便微生物群疗法等14条建议。
要点
- 非暴发型艰难梭菌感染首选非达霉素200 mg每日两次口服10天,因复发率较低;万古霉素125 mg每日四次口服10天也可接受;甲硝唑不用于暴发型以外的患者。
- 暴发型艰难梭菌感染(休克、肠梗阻或巨结肠)需多学科团队管理,给予万古霉素500 mg每6小时口服或肠内给药,联合甲硝唑500 mg每8小时静脉给药;若存在肠梗阻,加用万古霉素500 mg每6小时直肠给药。
- 白细胞>15,000 cells/uL和/或肌酐>1.5倍基线提示重度感染及复发和不良结局风险增加。
- 首次复发(完成治疗后8周内第二次发作)应使用万古霉素递减疗程或非达霉素治疗,并评估复发风险及考虑微生物群恢复疗法。
- 不推荐常规治愈检测;仅在腹泻症状持续加重时进行粪便检测。不推荐用万古霉素预防艰难梭菌感染,不推荐益生菌预防初发或复发感染。
适用人群与场景
- 成人艰难梭菌感染患者,包括住院患者(需在诊断时分为非重度、重度或暴发型)
- 有艰难梭菌感染病史者应特别告知避免不必要的抗生素治疗
- 多次复发且因持续合并症、预期寿命有限或持续/频繁全身抗生素使用而不适合粪便微生物群疗法,或多次粪便微生物群疗法失败者,可考虑长期低剂量万古霉素抑制方案(125 mg每日一次)作为二级预防
诊断标准与关键阈值
- 艰难梭菌感染为临床诊断,需 compatible 症状(通常为抗生素后急性腹泻)结合支持性实验室检测;多步检测首选以提高诊断准确性。
- 白细胞>15,000 cells/uL和/或肌酐>1.5倍基线提示重度艰难梭菌感染及复发和不良结局风险增加。
- 存在休克、肠梗阻或巨结肠等额外表现者为暴发型艰难梭菌感染,可致命。
处置流程与药物剂量
- 预防:医疗机构内使用美国环境保护署批准的杀孢子剂进行屏障防护和消毒;告知患者手卫生重要性,考虑对家庭中可能被艰难梭菌孢子污染的区域进行消毒以防再感染;可安慰患者向未受影响家庭成员传播不常见。
- 非暴发型艰难梭菌感染:非达霉素200 mg每日两次口服,疗程10天,为首选;或因实际考虑,万古霉素125 mg每日四次口服,疗程10天,也可接受;甲硝唑不用于暴发型以外的患者。
- 暴发型艰难梭菌感染:多学科团队(消化科/感染科、外科、内科/重症监护)管理;万古霉素500 mg每6小时口服或肠内给药,联合甲硝唑500 mg每8小时静脉给药;若存在肠梗阻,加用万古霉素500 mg每6小时直肠给药。
- 首次复发(完成抗艰难梭菌感染治疗后8周内第二次发作):使用万古霉素递减疗程或非达霉素治疗;治疗应包括复发风险评估和考虑微生物群恢复疗法以预防复发。
- 第二次复发后(第三次艰难梭菌感染发作):应提供粪便微生物群疗法(粪便微生物群孢子,live-brpk;粪便微生物群,live-jslm;或传统粪菌移植)。
- 对于进一步复发高风险或初发感染特别病重或难以治疗的患者,可在初发感染或首次复发治疗后考虑微生物群恢复疗法。
- 不推荐在全身抗生素使用期间使用万古霉素预防艰难梭菌感染;不推荐益生菌预防初发或复发艰难梭菌感染;应指导患者摄入健康饮食,包括多种水果和蔬菜,富含可溶性和不可溶性纤维,以促进健康肠道微生物群恢复。
- 治疗艰难梭菌感染或预防复发期间,应评估质子泵抑制剂的使用;若存在合理适应症,无需停用质子泵抑制剂。
红旗征与不能漏的情况
- 暴发型艰难梭菌感染:存在休克、肠梗阻或巨结肠,可致命,需多学科团队管理并给予大剂量万古霉素联合静脉甲硝唑,肠梗阻时加用直肠万古霉素。
- 白细胞>15,000 cells/uL和/或肌酐>1.5倍基线提示重度感染及复发和不良结局风险增加。
- 检测结果不一致但临床高度怀疑艰难梭菌感染者应予以治疗。
研究设计与关键结果
- 该专家综述由AGA临床实践更新委员会和AGA理事会委托,基于专家意见和已发表文献回顾制定,未进行系统评价,故最佳实践建议无正式证据质量或强度评级。
- 综述经过实践更新委员会内部同行评议和《Clinical Gastroenterology and Hepatology》标准程序的外部同行评议。
证据类型、等级与局限
- 证据类型:专家综述(专家意见结合文献回顾),未进行系统评价,建议无正式证据质量或强度评级。
- 局限:原文未报告局限性
对床旁实践的改变
- 非暴发型艰难梭菌感染首选非达霉素200 mg每日两次口服10天,万古霉素125 mg每日四次口服10天也可接受,甲硝唑不用于暴发型以外的患者。
- 暴发型艰难梭菌感染需多学科团队管理,使用万古霉素500 mg每6小时口服或肠内给药联合甲硝唑500 mg每8小时静脉给药,肠梗阻时加用万古霉素500 mg每6小时直肠给药。
- 不推荐常规治愈检测,仅在腹泻症状持续加重时进行粪便检测。
- 不推荐用万古霉素预防艰难梭菌感染,不推荐益生菌预防初发或复发感染;应评估质子泵抑制剂使用,有合理适应症者无需停用。
- 有艰难梭菌感染病史者应特别告知避免不必要的抗生素治疗。
指南或共识出处
- AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review
- 美国胃肠病学协会(AGA)
- Clinical Gastroenterology and Hepatology
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
DESCRIPTION: Clostridioides difficile infection is a common cause of clinically significant diarrhea, often becomes recurrent, and can be fatal when severe or fulminant. The purpose of this America Gastroenterological Association (AGA) Clinical Practice Update Expert Review is to provide best practice advice for C difficile infection management.
METHODS: This expert review was commissioned by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. The review was developed from expert opinion and a review of the published literature. Because systematic reviews were not performed, these best practice advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. The review underwent internal peer review by the Practice Updates Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. BEST PRACTICE ADVICE STATEMENTS BEST PRACTICE ADVICE 1: Prevention of C difficile infection should include proper barrier protection and disinfection with United States Environmental Protection Agency-approved sporicidal agents in health care settings. Patients should be counseled on the importance of handwashing and to consider disinfecting areas of the home potentially contaminated with C difficile spores, to prevent reinfection. Reassurance should be provided that C difficile infection transmission to unaffected family members is uncommon. BEST PRACTICE ADVICE 2: C difficile infection is a clinical diagnosis that requires compatible symptoms (typically acute diarrhea, following antibiotics) in combination with supportive laboratory testing. Multistep testing is preferred for best diagnostic accuracy; however, patients with discordant testing who have a high clinical suspicion for C difficile infection should be treated. BEST PRACTICE ADVICE 3: Clinicians should classify hospitalized patients with C difficile infection as having nonsevere, severe, or fulminant disease at diagnosis. White blood cell count >15,000 cells/uL and/or creatinine >1.5 × baseline are indicative of severe C difficile infection and increased risk for recurrence and poor outcomes. Patients with additional findings of shock, ileus, or megacolon have fulminant C difficile infection, which can be fatal. BEST PRACTICE ADVICE 4: Fidaxomicin (200 mg twice daily oral for 10 days) is a narrower spectrum agent, and given lower recurrence rates, is favored as first-line therapy for nonfulminant C difficile infection. However, given practical considerations, vancomycin (125 mg 4 times daily oral for 10 days) is also acceptable therapy. Metronidazole should not be used outside of fulminant disease. BEST PRACTICE ADVICE 5: Cholestyramine and other bile acid-binding agents should not be used as monotherapy or concurrently with oral vancomycin or fidaxomicin. Psyllium fiber can be used to bulk stools in patients who have recovered from the infection. BEST PRACTICE ADVICE 6: Following treatment of C difficile infection, clinicians should not perform routine test of cure. Stool testing should only be performed for persistent worsening of diarrheal symptoms. BEST PRACTICE ADVICE 7: First C difficile infection recurrence (second episode) within 8 weeks of completing anti-C difficile infection therapy should be treated with either a tapering course of vancomycin or fidaxomicin. Treatment of C difficile infection should include a risk assessment for C difficile infection recurrence and consideration of microbiota restoration therapy to prevent recurrence. BEST PRACTICE ADVICE 8: Fecal microbiota-based therapies (fecal microbiota spores, live-brpk, fecal microbiota, live-jslm, or conventional fecal microbiota transplant) should be offered after treatment of a second recurrence (third C difficile infection episode). Microbiota restoration therapy may be considered after treatment of an initial infection or first recurrence in patients who are at high risk for further recurrence or in patients whose initial C difficile infection episode was particularly morbid or difficult to treat. BEST PRACTICE ADVICE 9: Prolonged, low dose, suppressive vancomycin regimen (125 mg daily) for secondary prophylaxis may be considered in patients with multiple recurrent episodes who are not candidates for fecal microbiota-based therapies due to ongoing comorbidities, limited life expectancy, or ongoing/frequent systemic antibiotics or who have failed multiple courses of fecal microbiota-based therapy. BEST PRACTICE ADVICE 10: Fulminant C difficile infection should be managed by a multidisciplinary team (gastroenterology/infectious disease, surgery, medicine/critical care) and treated with high-dose vancomycin 500 mg every 6 hours (oral or enteral), with metronidazole 500 mg intravenously every 8 hours, and if ileus is present, rectal vancomycin 500 mg every 6 hours should be added. BEST PRACTICE ADVICE 11: Multi-dose fecal microbiota transplantation (fresh-directed donors, or institutional stool banks) delivered via lower endoscopy, should be considered in individuals with fulminant C difficile infection. Fecal microbiota, live-jslm (Rebyota), and fecal microbiota spores, live-brpk (Vowst) have not been studied and are not approved for treatment of severe and/or fulminant C difficile infection. Due to high risk of C difficile infection recurrence, patients who recover from severe or fulminant C difficile infection should be maintained on a suppressive vancomycin regimen until a final fecal microbiota transplantation can be administered as an outpatient. BEST PRACTICE ADVICE 12: Use of vancomycin is not advised during systemic antibiotic administration to prevent C difficile infection. Probiotics are not advised to prevent an initial or recurrent C difficile infection. To promote restoration of healthy gut microbiota, patients should be instructed to consume a healthy diet including a variety of fruits and vegetables, rich in both soluble and insoluble fiber. BEST PRACTICE ADVICE 13: During the treatment of C difficile infection or the prevention of its recurrence, the use of proton pump inhibitors should be evaluated. If a legitimate indication exists for their use, proton pump inhibitor discontinuation is not necessary. BEST PRACTICE ADVICE 14: Individuals with a history of C difficile infection should be specifically counseled to avoid unnecessary antibiotic therapy.
参考来源
- Fischer M, Vaughn BP, Peery AF, et al. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42383946. doi:10.1016/j.cgh.2026.05.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。